Press Release
| PSP001 (PEGIL29 Chimera) IND submission (FDA) |
| Date:2021-02-05 17:07:25 | Visits： |
|
| Prev:Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating Next:PSP001 received Safe-to-proceed Letter by FDA |
| PSP001 (PEGIL29 Chimera) IND submission (FDA) |
| Date:2021-02-05 17:07:25 | Visits： |
|
| Prev:Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating Next:PSP001 received Safe-to-proceed Letter by FDA |
Beijing Headquarter:
Add: A302 No.5 Kaituo Road, Haidian District, Beijing, China, 100085
Tel: +86-10-62975234
Manufacturing Facility & Laboratory:
Building No. 3, Peptide Valley, GuAn, Hebei, China
US Clinical Center:
Seattle, WA, USA